Ascletis Unveils Groundbreaking Fixed-Dose Combination Therapy for Obesity Management Ascletis Pharma announces a new fixed-dose combination of ASC30 and ASC39 aimed at obesity treatment, highlighting promising pharmacokinetics and patient compliance.

Ascletis Unveils Groundbreaking Fixed-Dose Combination Therapy for Obesity Management #USA #Hong_Kong #ASC30 #Ascletis_Pharma #ASC39

ASC39: A Promising Oral Small Molecule for Obesity Management in Clinical Trials Ascletis Pharma's ASC39 shows remarkable efficacy and selectivity in obesity treatment. The drug is poised for FDA review and clinical trials.

ASC39: A Promising Oral Small Molecule for Obesity Management in Clinical Trials #USA #Hong_Kong #Obesity_Treatment #Ascletis_Pharma #ASC39

Ascletis to Unveil New Obesity Treatments at ObesityWeek® 2025 Conference Ascletis to showcase results of ASC30 oral tablet and injection, along with ASC31 and ASC47 combination at ObesityWeek® 2025, Atlanta.

Ascletis to Unveil New Obesity Treatments at ObesityWeek® 2025 Conference #USA #Atlanta #ASC30 #Ascletis_Pharma #ObesityWeek

Ascletis Pharma Begins Phase I Study of Potential Psoriasis Treatment ASC50 in Healthy Participants Ascletis Pharma has initiated a Phase I clinical study of ASC50, an oral IL-17 inhibitor for psoriasis, showing promising safety and efficacy in early trials.

Ascletis Pharma Begins Phase I Study of Potential Psoriasis Treatment ASC50 in Healthy Participants #Hong_Kong #Ascletis_Pharma #ASC50 #Psoriasis_Treatment

Ascletis Showcases Innovative ASC47 Weight Loss Drug Research at European Congress on Obesity At the 32nd European Congress on Obesity, Ascletis will present findings on ASC47, a unique weight loss drug that aims to preserve muscle while promoting fat loss.

Ascletis Showcases Innovative ASC47 Weight Loss Drug Research at European Congress on Obesity #China #Hong_Kong #ASC47 #Ascletis_Pharma #ECO_2025

Ascletis Pharma's ASC30 Shows Promising Results in U.S. Phase Ib Obesity Trial Ascletis Pharma has announced encouraging interim results from its Phase Ib study of ASC30, a GLP-1R agonist, showing a potential monthly injection for obesity.

Ascletis Pharma's ASC30 Shows Promising Results in U.S. Phase Ib Obesity Trial #United_States #Hong_Kong #ASC30 #Ascletis_Pharma #GLP-1R

Ascletis Reveals Breakthrough Phase Ib Results for ASC47 Weight Loss Drug in the US and Australia Ascletis has released promising results from Phase Ib studies of ASC47, a novel obesity treatment, showcasing its efficacy and safety in patients.

Ascletis Reveals Breakthrough Phase Ib Results for ASC47 Weight Loss Drug in the US and Australia #USA #Hong_Kong #ASC47 #Obesity_Treatment #Ascletis_Pharma

Ascletis Reports Positive Interim Findings in Phase Ib Trial of ASC30 for Weight Loss Treatment Ascletis Pharma has highlighted encouraging interim results from the Phase Ib study of ASC30, an oral medication for obesity treatment, showing significant weight loss.

Ascletis Reports Positive Interim Findings in Phase Ib Trial of ASC30 for Weight Loss Treatment #USA #Hong_Kong #Obesity_Treatment #ASC30 #Ascletis_Pharma